Gaithersburg’s Vector BioMed launches with $15M to manufacture gene therapy technology

A new Gaithersburg biotech has launched with millions of dollars in new financing to make a key technology for gene therapy companies. The firm, called Vector BioMed Inc., raised $15 million in late 2022 and is now putting that money to work — to speed up its commercial operations and bring customers on board. It plans to manufacture lentiviral vectors, a type of therapy used to deliver genes into human cells in cases such as cancer and rare disease, and to supply those vectors to other biotechs developing and commercializing treatments that use them, Vector BioMed co-founder and CEO Boro Dropulić told the Washington Business Journal, a sister paper to the Baltimore Business Journal.